141 related articles for article (PubMed ID: 35593342)
21. Clinical Significance of TIPE2 Protein Upregulation in Non-Hodgkin's Lymphoma.
Hao C; Zhang N; Geng M; Ren Q; Li Y; Wang Y; Chen YH; Liu S
J Histochem Cytochem; 2016 Sep; 64(9):556-64. PubMed ID: 27578327
[TBL] [Abstract][Full Text] [Related]
22. Unusual presentation of diffuse large B-cell non-Hodgkin's lymphoma in children: bilateral ureteral involvement.
Kantar M; Hekimgil M; Harman M; Oral A; Öge Ö; Avanoglu A
Pediatr Hematol Oncol; 2019 Nov; 36(8):504-509. PubMed ID: 31566047
[TBL] [Abstract][Full Text] [Related]
23. CircRNA_OTUD7A upregulates FOXP1 expression to facilitate the progression of diffuse large B-cell lymphoma via acting as a sponge of miR-431-5p.
Liu W; Lei L; Liu X; Ye S
Genes Genomics; 2021 Jun; 43(6):653-667. PubMed ID: 33830472
[TBL] [Abstract][Full Text] [Related]
24. Non-Hodgkin's lymphoma involving the vagina: a clinicopathologic analysis of 14 patients.
Vang R; Medeiros LJ; Silva EG; Gershenson DM; Deavers M
Am J Surg Pathol; 2000 May; 24(5):719-25. PubMed ID: 10800991
[TBL] [Abstract][Full Text] [Related]
25. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Prichard M; Harris T; Williams ME; Densmore JJ
Expert Opin Pharmacother; 2009 Apr; 10(6):983-95. PubMed ID: 19364248
[TBL] [Abstract][Full Text] [Related]
26. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
[TBL] [Abstract][Full Text] [Related]
27. The relationship between Hodgkin's disease and non-Hodgkin's lymphoma.
Harris NL
Semin Diagn Pathol; 1992 Nov; 9(4):304-10. PubMed ID: 1480853
[TBL] [Abstract][Full Text] [Related]
28. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.
Du H; Gao L; Luan J; Zhang H; Xiao T
Acta Haematol; 2019; 142(2):64-70. PubMed ID: 31096215
[TBL] [Abstract][Full Text] [Related]
29. The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas.
Jaffe ES; Zarate-Osorno A; Kingma DW; Raffeld M; Medeiros LJ
Ann Oncol; 1994; 5 Suppl 1():7-11. PubMed ID: 8172822
[TBL] [Abstract][Full Text] [Related]
30. Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas.
Shim HK; Lee WW; Park SY; Kim H; So Y; Kim SE
Nucl Med Biol; 2009 Feb; 36(2):191-7. PubMed ID: 19217531
[TBL] [Abstract][Full Text] [Related]
31. Repeated clonal relapses in classical Hodgkin's lymphoma and the occurrence of a clonally unrelated diffuse large B cell non-Hodgkin lymphoma in the same patient.
Thomas RK; Wickenhauser C; Kube D; Tesch H; Diehl V; Wolf J; Vockerodt M
Leuk Lymphoma; 2004 May; 45(5):1065-9. PubMed ID: 15291369
[TBL] [Abstract][Full Text] [Related]
32. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study.
Löfström B; Backlin C; Sundström C; Ekbom A; Lundberg IE
Ann Rheum Dis; 2007 Dec; 66(12):1627-32. PubMed ID: 17517757
[TBL] [Abstract][Full Text] [Related]
33. [Research on Ralation of Long Non-coding RNA with Diffuse Large B-cell Lymphomas -Review].
Wu YY; Xing YR; Yu DN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):609-614. PubMed ID: 29665941
[TBL] [Abstract][Full Text] [Related]
34. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.
Mahadevan D; Spier C; Della Croce K; Miller S; George B; Riley C; Warner S; Grogan TM; Miller TP
Mol Cancer Ther; 2005 Dec; 4(12):1867-79. PubMed ID: 16373702
[TBL] [Abstract][Full Text] [Related]
35. Primary testicular diffuse large B-cell lymphoma: Case series.
Wang Q; Zheng D; Chai D; Wu S; Wang X; Chen S; Wu L; Cao R; Tao Y
Medicine (Baltimore); 2020 Mar; 99(12):e19463. PubMed ID: 32195944
[TBL] [Abstract][Full Text] [Related]
36. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
37. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of parameters with potential prognosis impact in patients with primary gastric diffuse large B-cell lymphoma (PG-DLBCL).
Rotaru I; Găman GD; Stănescu C; Găman AM
Rom J Morphol Embryol; 2014; 55(1):15-21. PubMed ID: 24715160
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study.
Lee SJ; Suh CW; Lee SI; Kim WS; Lee WS; Kim HJ; Choi CW; Kim JS; Shin HJ;
Korean J Intern Med; 2014 May; 29(3):352-60. PubMed ID: 24851070
[TBL] [Abstract][Full Text] [Related]
40. A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma-diffuse large B-cell lymphoma (DOBL study): Study protocol and design.
Goda JS; Lewis SC; Laskar S; Kannan S; Khanna N; Jain H; Bagal B; Epari S
Cancer Rep (Hoboken); 2019 Apr; 2(2):e1161. PubMed ID: 32935480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]